Published in Drug Saf on January 01, 2005
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res (2011) 2.41
Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol (2012) 1.17
Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol (2008) 1.07
Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol (2006) 1.07
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol (2005) 1.02
The impact of varying autonomic states on the dynamic beat-to-beat QT-RR and QT-TQ interval relationships. Br J Pharmacol (2008) 1.00
Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol (2010) 0.97
Early QT assessment--how can our confidence in the data be improved? Br J Clin Pharmacol (2013) 0.94
Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel. Br J Pharmacol (2009) 0.93
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol (2007) 0.86
The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker. PLoS One (2012) 0.82